We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| KalVista Pharmaceuticals Inc | NASDAQ:KALV | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.08 | -0.66% | 12.00 | 9.50 | 13.52 | 12.43 | 11.91 | 12.15 | 206,932 | 21:03:37 |
From May 2023 to May 2024
By Chris Wack
KalVista Pharmaceuticals said Monday it has hit a milestone in its clinical trial for its lead program sebetralstat, in development as a potential oral on-demand therapy for hereditary angioedema.
The clinical-stage pharmaceutical company has achieved the targeted number of on-treatment attacks required to complete the phase 3 trial.
The trial is a cross-over study in which patients are intended to treat a total of three attacks: one each with 300 mg sebetralstat, 600 mg sebetralstat and placebo, given in a randomized sequence.
KalVista expects topline data in early 2024, remaining on track for a New Drug Application submission to the U.S. Food and Drug Administration in the first half of 2024. The company also expects to file for approval in the European Union and Japan later in 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 13, 2023 06:58 ET (11:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year KalVista Pharmaceuticals Chart |
1 Month KalVista Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
